Updated interim data from the phase 1 portion of the ongoing NTLA-2002 phase 1/2 study, analyzing the experimental drug for the treatment of hereditary angioedema (HAE), will be presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2023, Intellia Therapeutics announced.
The EAACI congress will take place June 9-11 virtually and in Hamburg, Germany.
“NTLA-2002 is an in vivo genome editing candidate designed to inactivate the target gene kallikrein B1 to permanently reduce plasma kallikrein protein levels and activity and thus prevent HAE attacks after a single-dose treatment. The presentation will include updated safety and efficacy results from the phase 1 portion of the study across all three dose cohorts (25 mg, 50 mg, and 75 mg),” company officials wrote in a press release.
Continue Reading
The presentation will include new safety, kallikrein reduction, and attack rate data across all dose cohorts in the phase 1 portion of the study.
Read more about HAE experimental therapies
The phase 1/2 study is assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adult patients with type 1 or 2 HAE. The researchers are set to monitor plasma kallikrein protein levels and activity, as well as the HAE attack rate.
In 2022, the clinical-stage genome editing company reported positive interim results from the phase 1 study. According to that data, the experimental drug may cause significant dose-dependent reductions in plasma kallikrein activity as well as reduce the frequency of HAE attacks.
Reference
Intellia Therapeutics to present updated interim data from ongoing phase 1/2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) at the EAACI Hybrid Congress 2023. News release. Intellia Therapeutics, Inc.; May 31, 2023.
